IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Erscheinungsjahr: 2021
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Breder, Valeriy Vladimirovich (Autor)
Vogel, Arndt (Autor)
Merle, Philippe (Autor)
Finn, Richard S. (Autor)
Galle, Peter R. (Autor)
Zhu, Andrew X. (Autor)
Cheng, Ann-Lii (Autor)
Feng, Yin-Hsun (Autor)
Li, Daneng (Autor)
Gaillard, Vincent E. (Autor)
Li, Lindong (Autor)
Nicholas, Alan (Autor)
Lencioni, Riccardo (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
